Precision Medicine and Pharmacogenetics: Stratification and Improved Outcome in Non-Small Cell Lung Cancer

Lung cancer is the most common globally, accounting for a quarter of all cancer-related deaths. Non-small cell lung (NSCLC) major subtype. Research in last few decades has led to identification key molecular targets resulting targeted therapies, such as use tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptors (EGFR). EGFR-TKIs themselves have evolved through generations based on knowledge gained from gene mutations EGFR leading therapy resistance. As part pharmacogenetics, it well known that patients often respond differentially different their genetic makeup. This opened up avenues precision medicine treatment NSCLC with and optimum strategy. Since time essence, critical be administered they are likely to. Evolving data validates this notion expected an approach will invariably lead improved patient outcomes.